MPRD (190156124)

  https://cordis.europa.eu/project/id/190156124

  Horizon Europe (2021-2027)

  Innovative, minimally invasive Medical Prostatic Retraction Device for the treatment of Benign Prostatic Hyperplasia (BPH) Patients in the office settings.

  EIC Accelerator Open 2023 (HORIZON-EIC-2023-ACCELERATOROPEN-01)

  surgery  ·  pharmaceutical drugs  ·  anaesthesiology

  2023-09-01 Start Date (YY-MM-DD)

  2025-08-31 End Date (YY-MM-DD)

  € 4,823,931

  Description

Butterfly Medical, a medical-device start-up, is developing a fast, simple, and minimally invasive alternative treatment to medication and surgery used for Benign Prostate Hyperplasia (BPH) treatment. Butterfly’s innovative device transfers the procedure from the operating room to the clinic, with the device being placed in 6 to 8 minutes, in doctor’s office, under local anaesthesia. Butterfly’s unique anatomically shaped proprietary nitinol implant is positioned in the prostatic urethra in order to open the urine path in the prostate for improved urine flow thereby relieving BPH symptoms. Implant doesn’t require any resection, cutting, or ablation of prostatic tissue. FIH clinical trials involving 85 patients performed in leading medical centres in Israel show a high degree of safety and effectiveness. Through this EIC project, Butterfly will undertake post-marketing studies in leading medical centres in Europe, and pivotal FDA study in the US.

  Complicit Organisations

1 Israeli organisation participates in MPRD.